NCT05567367View on ClinicalTrials.gov

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

December 4, 2019

Study Completion Date

December 4, 2019

Conditions
Healthy Volunteer
Interventions
COMBINATION_PRODUCT

Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.

DRUG

Vardenafil Oral Tablet

20 mg oral vardenafil tablet.

Trial Locations (1)

3004

Nucleus Network, Burnet Institute, Prahran

All Listed Sponsors
lead

Respira Therapeutics, Inc.

INDUSTRY

NCT05567367 - A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234 | Biotech Hunter | Biotech Hunter